公开(公告)号：EP1614424A1

公开(公告)日：2006-01-11

申请号：EP04726619.2

申请日：2004-04-08

申请人： Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute

发明人： TAGAWA, R.; c/o J. F. Chemo-Sero-Theraupic R. I. ,  HAYASE, Y.; c/o J. F. Chemo-Sero-Theraupic R. I. ,  MAEMURA, K.; c/o J. F. Chemo-Sero-Theraupic R. I. ,  TANIGAWA, H.; c/o J. F. Chemo-Sero-Theraupic R. I.

IPC分类号： A61K38/38 ,  B01D61/14

CPC分类号： C07K14/76 ,  A61K38/38 ,  B01D61/147

摘要： An albumin preparation may be produced efficiently on a commercial basis that has reduced possibility of contamination of infectious viruses and has high safety and stability. The process according to the present invention comprises a step of filtration of a serum albumin-containing solution with a virus-removing membrane preferably with a pore size of 10 to 20 nm. In particular, said filtration is performed before heat treatment for inactivation of viruses. In a more preferable embodiment, said serum albumin-containing solution is treated with an anion exchanger and/or a prefilter before a step of said filtration.

摘要翻译： 可以商业上有效地生产白蛋白制剂，其具有降低感染性病毒污染的可能性并且具有高的安全性和稳定性。 根据本发明的方法包括用优选具有10至20nm的孔径的病毒除去膜过滤含血清白蛋白的溶液的步骤。 特别地，所述过滤在用于灭活病毒的热处理之前进行。 在更优选的实施方案中，所述含血清白蛋白的溶液在所述过滤步骤之前用阴离子交换剂和/或预过滤器处理。